AbbVie begins construction of $70 million biologics manufacturing site in US
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Miels will formally assume the role on January 1, 2026
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The Hub & Spoke model is designed to extend advanced medical care to a wider community
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Subscribe To Our Newsletter & Stay Updated